Artiva Biotherapeutics (ARTV) Income from Continuing Operations: 2023-2024
Historic Income from Continuing Operations for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$16.1 million.
- Artiva Biotherapeutics' Income from Continuing Operations fell 41.30% to -$16.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$61.9 million, marking a year-over-year change of. This contributed to the annual value of -$65.4 million for FY2024, which is 127.62% down from last year.
- Latest data reveals that Artiva Biotherapeutics reported Income from Continuing Operations of -$16.1 million as of Q4 2024, which was up 2.42% from -$16.5 million recorded in Q3 2024.
- Artiva Biotherapeutics' Income from Continuing Operations' 5-year high stood at $11.2 million during Q3 2023, with a 5-year trough of -$16.7 million in Q2 2023.
- Over the past 2 years, Artiva Biotherapeutics' median Income from Continuing Operations value was -$15.5 million (recorded in 2024), while the average stood at -$11.3 million.
- Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Income from Continuing Operations showed a top increase of 6.90% in 2024 and a maximum decrease of 246.84% in 2024.
- Artiva Biotherapeutics' Income from Continuing Operations (Quarterly) stood at -$11.4 million in 2023, then tumbled by 41.30% to -$16.1 million in 2024.
- Its Income from Continuing Operations stands at -$16.1 million for Q4 2024, versus -$16.5 million for Q3 2024 and -$15.5 million for Q2 2024.